DrugPatentWatch Database Preview
Patent: 9,539,263
» See Plans and Pricing
Summary for Patent: 9,539,263
| Title: | Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis |
| Abstract: | The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed. |
| Inventor(s): | Zhang; Xiaoping (Wayne, NJ), Terao; Kimio (Funabashi, JP), Jahreis; Angelika M. (Menlo Park, CA) |
| Assignee: | Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche, Inc. (Nutley, NJ) Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) |
| Application Number: | 14/062,005 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,539,263
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | ACTEMRA | tocilizumab | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 125472 | 001 | 2013-10-21 | Start Trial | Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche, Inc. (Nutley, NJ) Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) | 2030-11-08 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 003 | 2010-01-08 | Start Trial | Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche, Inc. (Nutley, NJ) Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) | 2030-11-08 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 002 | 2010-01-08 | Start Trial | Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche, Inc. (Nutley, NJ) Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) | 2030-11-08 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche, Inc. (Nutley, NJ) Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) | 2030-11-08 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,539,263
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2012064627 | Start Trial |
| United States of America | 10231981 | Start Trial |
| United States of America | 2012301460 | Start Trial |
| United States of America | 2014056883 | Start Trial |
| United States of America | 2014056884 | Start Trial |
| United States of America | 2014056885 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
